摘要
目的探究COL1A2的表达与肺腺癌患者临床病理特征和预后的关系。方法从癌症基因组图谱(The Cancer Genome Atlas,TCGA)数据库中下载TCGA-肺腺癌的RNA-Seq表达谱和相应的临床数据,通过生物信息学分析COL1A2在肺腺癌组织与正常肺组织中的表达差异及与肺腺癌患者生存率的关系。收集2018年1月~2020年12月石河子大学第一附属医院收治的肺腺癌患者82例,采用免疫组化法验证COL1A2的表达与肺腺癌患者临床病理特征及预后的关系。结果COL1A2在肺腺癌组织中呈高表达(P<0.05)。免疫组化结果表明,COL1A2表达与肺腺癌患者TNM分期及是否有远处转移有关(P<0.05);Kaplan-Meier生存分析结果表明,COL1A2的表达与肺腺癌患者预后相关(χ^(2)=9.639,P=0.002);多因素COX回归分析结果表明,COL1A2高表达是肺腺癌患者预后的独立危险因素(HR=2.657,95%CI:1.062~6.646,P=0.037)。结论COL1A2在肺腺癌中呈高表达,与肺腺癌患者肿瘤分期、是否有远处转移及预后相关。
Objective To investigate the relationship between COL1A2 expression and clinicopathological characteristics and prognosis of patients with lung adenocarcinoma.Methods The RNA-Seq expression profile of TCGA-lung adenocarcinoma and corresponding clinical data were downloaded from The Cancer Genome Atlas(TCGA)database,bioinformatics was used to analyze the correlation between the differential expression of COL1A2 in lung adenocarcinoma tissues compared to normal lung tissues and the survival rate of patients with lung adenocarcinoma.Eighty-two patients with lung adenocarcinoma were selected from January 2018 to December 2020 in the First Affiliated Hospital of Shihezi University.Using immunohistochemistry to verify the relationship between COL1A2 expression and clinicopathological characteristics and prognosis of patients with lung adenocarcinoma.Results COL1A2 was highly expressed in lung adenocarcinoma tissues(P<0.05).Immunohistochemistry indicated that COL1A2 expression was associated with tumour stage and the presence of distant metastases(P<0.05).Kaplan-Meier survival analysis indicated COL1A2 expression was associated with the prognosis of patients with lung adenocarcinoma(χ^(2)=9.639,P=0.002).Multivariate COX regression analysis showed that high expression of COL1A2 was an independent risk factor for prognosis of patients with lung adenocarcinoma(HR=2.657,95%CI:1.062-6.646,P=0.037).Conclusion The expression of COL1A2 is elevated in lung adenocarcinoma,which correlates with tumour stage,presence of distant metastasis and prognosis of patients with lung adenocarcinoma.
作者
杨小璇
王延玲
李晶
巩平
YANG Xiaoxuan;WANG Yanling;LI Jing(Shihezi University,Xinjiang 832000,China;不详)
出处
《医学研究杂志》
2024年第9期157-161,共5页
Journal of Medical Research
基金
石河子大学青年创新人才计划项目(CXPY202319)。
关键词
COL1A2
肺腺癌
临床病理特征
预后
免疫组化法
COL1A2
Lung adenocarcinoma
Clinicopathological characteristics
Prognosis
Immunohistochemistry
